{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:30:23Z","timestamp":1790746223558,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Communications"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis. We assessed the efficacy and durability of short and prolonged CVC therapy in a diet\u2010induced mouse model of NASH, the choline deficient, L\u2010amino acid\u2010defined, high\u2010fat diet (CDAHFD) model. C57BL\/6 mice received 4 or 14 weeks of standard chow or the CDAHFD. CVC (10 mg\/kg\/day and 30 mg\/kg\/day for 4 weeks and 20 mg\/kg\/day and 30 mg\/kg\/day for 14 weeks) was initiated simultaneously with the CDAHFD. At 4 and 14 weeks, livers were harvested for histology and flow cytometric analyses of intrahepatic immune cells. High\u2010dose CVC (30 mg\/kg\/day) therapy in CDAHFD mice for 4 or 14 weeks inhibited intrahepatic accumulation of Ly6C<jats:sup>high<\/jats:sup> bone marrow\u2010derived macrophages. Prolonged CVC therapy (14 weeks) yielded no significant differences in the total intrahepatic macrophage populations among treatment groups but increased the frequency of intrahepatic anti\u2010inflammatory macrophages in the high\u2010dose CVC group. Despite ongoing steatohepatitis, there was significantly less fibrosis in CDAHFD mice receiving high\u2010dose CVC for 14 weeks based on histologic and molecular markers, mirroring observations in human NASH CVC trials. CVC also directly inhibited the profibrotic gene signature of transforming growth factor\u2010\u03b2\u2010stimulated primary mouse hepatic stellate cells <jats:italic toggle=\"yes\">in vitro<\/jats:italic>. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> CVC is a novel therapeutic agent that is associated with reduced fibrosis despite ongoing steatohepatitis. Its ability to alter intrahepatic macrophage populations and inhibit profibrogenic genes in hepatic stellate cells in NASH livers may contribute to its observed antifibrotic effect. (<jats:italic toggle=\"yes\">Hepatology Communications<\/jats:italic> 2018;2:529\u2010545)<\/jats:p>","DOI":"10.1002\/hep4.1160","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T13:36:36Z","timestamp":1520429796000},"page":"529-545","source":"Crossref","is-referenced-by-count":62,"title":["Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet\u2010induced mouse model of nonalcoholic steatohepatitis"],"prefix":"10.1097","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-5996","authenticated-orcid":false,"given":"Annie J.","family":"Kruger","sequence":"first","affiliation":[{"name":"Gastrointestinal Unit,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan C.","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Department of Surgery,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Masia","sequence":"additional","affiliation":[{"name":"Department of Pathology,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta A.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit,Massachusetts General Hospital and Harvard Medical School,Boston,MA"},{"name":"Department of Gastroenterology,St. Vincent's Hospital,Fitzroy,VIC,Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Salloum","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhdeh","family":"Sojoodi","sequence":"additional","affiliation":[{"name":"Department of Surgery,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego S.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital,Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Rutledge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital,Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Caravan","sequence":"additional","affiliation":[{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital,Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Alatrakchi","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Vig","sequence":"additional","affiliation":[{"name":"Allergan Plc.,South San Francisco,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Allergan Plc.,South San Francisco,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Gastrointestinal Unit,Massachusetts General Hospital and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"hep41160-bib-0001-20240220","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","year":"2015","journal-title":"JAMA"},{"key":"hep41160-bib-0002-20240220","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis\u2010associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"hep41160-bib-0003-20240220","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: current burden and expected challenges","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep41160-bib-0004-20240220","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.3748\/wjg.v20.i42.15532","article-title":"Liver transplantation and non\u2010alcoholic fatty liver disease","volume":"20","year":"2014","journal-title":"World J Gastroenterol"},{"key":"hep41160-bib-0005-20240220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","year":"2016","journal-title":"Clin Liver Dis"},{"key":"hep41160-bib-0006-20240220","first-page":"5170402","article-title":"Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells","volume":"2016","year":"2016","journal-title":"Biomed Res Int"},{"key":"hep41160-bib-0007-20240220","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"hep41160-bib-0008-20240220","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"hep41160-bib-0009-20240220","doi-asserted-by":"crossref","first-page":"e112327","DOI":"10.1371\/journal.pone.0112327","article-title":"Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep41160-bib-0010-20240220","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP\u20101) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","year":"2012","journal-title":"Gut"},{"key":"hep41160-bib-0012-20240220","doi-asserted-by":"crossref","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep41160-bib-0013-20240220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non\u2010alcoholic steatohepatitis","volume":"94","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"hep41160-bib-0014-20240220","doi-asserted-by":"crossref","first-page":"e0127991","DOI":"10.1371\/journal.pone.0127991","article-title":"Mouse models of diet\u2010induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep41160-bib-0015-20240220","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"hep41160-bib-0016-20240220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2015.04.029","article-title":"3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep41160-bib-0017-20240220","doi-asserted-by":"crossref","first-page":"e0128387","DOI":"10.1371\/journal.pone.0128387","article-title":"Localized CCR2 activation in the bone marrow niche mobilizes monocytes by desensitizing CXCR4","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep41160-bib-0019-20240220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"hep41160-bib-0020-20240220","first-page":"81","article-title":"The elusive antifibrotic macrophage","volume":"2","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"hep41160-bib-0022-20240220","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1189\/jlb.4A0415-152R","article-title":"Hepatic CD206\u2010positive macrophages express amphiregulin to promote the immunosuppressive activity of regulatory T cells in HBV infection","volume":"98","year":"2015","journal-title":"J Leukoc Biol"},{"key":"hep41160-bib-0023-20240220","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","year":"2017","journal-title":"Hepatology"},{"key":"hep41160-bib-0024-20240220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ni.1853","article-title":"CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes","volume":"11","year":"2010","journal-title":"Nat Immunol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep4.1160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/02009842-201805000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:02:56Z","timestamp":1708444976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02009842-201805000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1160","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]}}}